Across TCGA pan-cancer cohorts, ZFAND2A-DT RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated ZFAND2A-DT data layer.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ZFAND2A-DT RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ZFAND2A-DT expression acts as an unfavorable survival marker, although some lineages such as PAAD and UCS show a favorable association.
KIRC, ACC, and BLCA are the cancer types where ZFAND2A-DT RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.